The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Mutations in NRAS codon 61, KRAS codon 146, and BRAF V600E as prognostic factors in patients who received anti-EGFR antibody for metastatic colorectal cancer.
Naoki Takahashi
No relevant relationships to disclose
Yasuhide Yamada
No relevant relationships to disclose
Hirokazu Taniguchi
No relevant relationships to disclose
Kohei Akiyoshi
No relevant relationships to disclose
Yoshitaka Honma
No relevant relationships to disclose
Satoru Iwasa
No relevant relationships to disclose
Ken Kato
No relevant relationships to disclose
Tetsuya Hamaguchi
No relevant relationships to disclose
Yasuhiro Shimada
No relevant relationships to disclose